关注并星标CPHI制药在线Bcl-2抑制剂“水土不服”2025年6月16日,艾伯维宣布Bcl-2抑制剂维奈克拉(Venetoclax)联合阿扎胞苷一线治疗高危骨髓增生异常综合征(HR-MDS)的三期临床VERONA宣告失败。从关键数据来看,此次试验的总生存期(OS)结果不尽人意,风险比(HR)为0.908,这一数值接近1,意味着维奈克拉联合方案与对照组在生存获益上几乎没有差异;而p值为0.3772...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.